<DOC>
	<DOCNO>NCT00087568</DOCNO>
	<brief_summary>This study evaluate efficacy , safety tolerability PEGASYS plus ribavirin patient CHC could tolerate responsive 12 week therapy PEG-Intron plus ribavirin . The anticipated time study treatment 1-2 year , target sample size &gt; 100 individual .</brief_summary>
	<brief_title>A Study PEGASYS ( Peginterferon Alfa-2a ( 40KD ) ) Combination With Ribavirin Patients With Chronic Hepatitis C ( CHC ) Previously Treated With PEG-Intron + Ribavirin</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>adult patient least 18 year age CHC infection , genotype 1 unable tolerate responsive PEGIntron + ribavirin therapy 12 week treatment use 2 form contraception study men woman woman pregnant breastfeed medical condition associate chronic liver disease ( eg , hemochromatosis , autoimmune hepatitis , alcoholic liver disease , toxin exposure ) patient decompensated cirrhosis patient receive systemic antiviral therapy investigational drug , PEGIntron + ribavirin , 24 week prior first dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>